There have been no additional reports of a serious brain infection known as progressive multifocal leukoencephalopathy, or PML, among patients taking the multiple-sclerosis drug Tysabri, the drug’s makers said Thursday.
Biogen Idec Inc. and Elan Corp., also said there were no reports of other “serious opportunistic infections,” as of April 23. The companies released the first safety update involving Tysabri since the drug was allowed back in the U.S. market last June. The data was released at the American Academy of Neurology’s annual meeting on Boston.
Click here for the whole article or google “New Tysabri Reports”
- I tweet regularly about minimalism, simple living, and #project333 here: @bemoreithless - Come on over and say hello! 4 years ago
- RT @wegoamanda: My latest blog feature on The Ride Project's @CourtneyCarver and her #MS blog story: http://ning.it/aQLyKG 7 years ago
- RT @MyelinRepairFdn: Congratulations to Scott Johnson for being selected as a finalist for Ernst & Young's Entrepreneur Of The Year... h ... 7 years ago
- RT @ThisIsSethsBlog: Seth's Blog: Will you miss them if they leave? (Call for linchpins) http://bit.ly/an0RhP 7 years ago
- RT @thebowenagency: Intro: RuthAnn Bowen, owner of The Bowen Agency PR, helping start ups and small businesses who don't know zip about ... 7 years ago